The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Open accessAbstract
In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strong evidence supports the ef fi cacy and cost-effectiveness of nutrition therapy as a component of quality diabetes care, including its integration into the medical management of diabetes”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [2]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,014
Tinahones, F. J., Gallwitz, B., Nordaby, M., Götz, S., Maldonado‐Lutomirsky, M., Woerle, H. J., & Broedl, U. C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12814 · Cited by 52
Genomic Characterization of Metformin Hepatic Response
Luizon, M. R., Eckalbar, W. L., Wang, Y., Jones, S. L., Smith, R. P., Megan, L., Lin, L., Gallins, P. J., Etheridge, A. S., Wright, F. A., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006449 · Cited by 52
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 52
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 52
Chan, C.-W., Yu, C.-L., Lin, J., Hsieh, Y., Lin, C., Hung, C.-Y., Li, C.-H., Liao, Y., Lo, C., Huang, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0663-6 · Cited by 52
Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 53
Dardi, I., Kouvatsos, T., & Jabbour, S. A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.09.005 · Cited by 52
Marincic, P. Z., Salazar, M. V., Hardin, A., Scott, S., Fan, S. X., Gaillard, P. R., Wyatt, C., Watson, L., Green, P., Glover, P., et al. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.06.303 · Cited by 51
Lingvay, I., Bergenheim, S. J., Buse, J. B., Freitas, P., Garvey, W. T., Harder-Lauridsen, N. M., Rosenstock, J., Sahu, K., & Wharton, S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00225-6 · Cited by 51
Self-citationShould Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 51
Gordon, J. P., McEwan, P. C., IDRIS, I. R., Evans, M., & Puelles, J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000512 · Cited by 51
2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 51
Rocha‐Ferreira, E., Poupon-Bejuit, L., Zelco, A., Leverin, A., Nair, S., Jonsdotter, A., Carlsson, Y., Thornton, C., Hagberg, H., & Rahim, A. A. (2018) · Brain · doi:10.1093/brain/awy220 · Cited by 51
Unosson, J., Wågsäter, D., Bjarnegård, N., Basso, R. D., Welander, M., Mani, K., Gottsäter, A., & Wanhainen, A. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.06.039 · Cited by 51
Diabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50
Newman, A. A., Grimm, N. C., Wilburn, J. R., Schoenberg, H. M., Trikha, S. R. J., Luckasen, G. J., Biela, L. M., Melby, C. L., & Bell, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01741 · Cited by 50
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride
Metry, M., Shu, Y., Abrahamsson, B., Cristofoletti, R., Dressman, J., Groot, D. W., Parr, A. F., Langguth, P., Shah, V. P., Tajiri, T., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.01.011 · Cited by 50
Clinical Decision Support System for Diabetes Based on Ontology Reasoning and TOPSIS Analysis
Chen, R.-C., Jiang, H. Q., Huang, C.-Y., & Bau, C.-T. (2017) · Journal of Healthcare Engineering · doi:10.1155/2017/4307508 · Cited by 50
Mody, R., Grabner, M., Yu, M. B., Turner, R., Kwan, A. Y. M., York, W., & Landó, L. F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1421146 · Cited by 50
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Griffin, S. J., Bethel, M. A., Holman, R. R., Khunti, K., Wareham, N. J., Brierley, G., Davies, M. J., Dymond, A., Eichenberger, R., Evans, P. H., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22180 · Cited by 50
Wilding, J. P. H., Godec, T. R., Khunti, K., Pocock, S., Fox, R. A., Smeeth, L. L., Clauson, P., Fenici, P., Hammar, N., & Medina, J. (2018) · BMC Medicine · doi:10.1186/s12916-018-1085-8 · Cited by 50
Patient and physician preferences for type 2 diabetes medications: a systematic review
Toroski, M., Kebriaeezadeh, A., Esteghamati, A., Karyani, A. K., Abbasian, H., & Nikfar, S. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00449-4 · Cited by 50
Nicolucci, A., Ceriello, A., Bartolo, P. D., Corcos, A., & Federici, M. O. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00732-w · Cited by 50
Mansour, A. A., Alibrahim, N. T. Y., Alidrisi, H. A., Alhamza, A. H. A., Almomin, A., Zaboon, I. A., Kadhim, M. B., Hussein, R. N., Nwayyir, H. A., Mohammed, A. G., et al. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.008 · Cited by 52
Drug-Drug Interactions at Organic Cation Transporter 1
Zhou, S., Zeng, S., & Shu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628705 · Cited by 50
AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus
Kim, E., & Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0472-0 · Cited by 49
Impact of frailty in older patients with diabetes mellitus: An overview
Cobo, A., Vázquez, L. A., Reviriego, J., & Rodríguez‐Mañas, L. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.01.004 · Cited by 51
Investigational insulin secretagogues for type 2 diabetes
Scheen, A. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152260 · Cited by 49
Basal Insulin Use With GLP-1 Receptor Agonists
Anderson, S. L., & Trujillo, J. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.152 · Cited by 49
Ramakrishna, R., Sarkar, D., Manduri, A., Iyer, S. G., & Shetty, K. (2017) · Journal of Food Science and Technology · doi:10.1007/s13197-017-2828-9 · Cited by 49
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 49
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Åhrén, B. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12911 · Cited by 49
Mobula, L. M., Sarfo, F. S., Carson, K. A., Burnham, G. M., Arthur, L., Ansong, D., Sarfo‐Kantanka, O., Plange‐Rhule, J., & Ofori‐Adjei, D. (2018) · Translational Metabolic Syndrome Research · doi:10.1016/j.tmsr.2018.09.001 · Cited by 49
Cassidy, S., Vaidya, V., Houghton, D., Zalewski, P., Seferović, J. P., Hallsworth, K., MacGowan, G. A., Trenell, M. I., & Jakovljević, D. G. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118816223 · Cited by 49
Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus
Syed, Y. Y., & McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0420-z · Cited by 49
Stepanova, N., Kolessnyk, M., Novakivskyi, V., Loboda, O., Snisar, L., & Shifris, І. (2015) · Zaporozhye Medical Journal · doi:10.14739/2310-1210 · Cited by 49
The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
Yang, W., Sun, X., Zhang, J., & Zhang, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108977 · Cited by 48
Li, T., Providencia, R. A., Jiang, W., Mu, N., Wang, Y., Li, X., Yin, Y., Liu, M., Yu, L., Gu, C., et al. (2022) · Drugs · doi:10.1007/s40265-021-01665-0 · Cited by 48
Goyal, S., Rani, J., Bhat, M. A., & Vanita, V. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.656 · Cited by 48
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
Kaku, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1099630 · Cited by 48
Abdul-Ghani, M. A. (2015) · Diabetes Care · doi:10.2337/dc14-2517 · Cited by 48
Perez‐Nieves, M., Kabul, S., Desai, U. S., Ivanova, J. I., Kirson, N. Y., Cummings, A. K. G., Birnbaum, H. G., Duan, R., Cao, D., & Hadjiyianni, I. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1135789 · Cited by 48
Nationale Versorgungsleitlinie (NVL) Diabetische Retinopathie
Ziemssen, F., Lemmen, K. D., Bertram, B., Hammes, H., & Agostini, H. T. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0315-8 · Cited by 48
Ghadge, A. A., & Kuvalekar, A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.08.009 · Cited by 48
Mansfield, C. A., Sikirica, M. V., Pugh, A., Poulos, C. M., Unmuessig, V., Moraño, R. B., & Martin, A. A. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0326-8 · Cited by 48
Normalizing fibromyalgia as a chronic illness
Clauw, D. J., D’Arcy, Y. M., Gebke, K. B., Semel, D., Pauer, L., & Jones, K. D. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1411743 · Cited by 48
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 48
Mansari, A. A., Obeid, Y., Islam, N., Fariduddin, M., Hassoun, A. A. K., Djaballah, K., Malek, M., Dicker, D., & Chaudhury, T. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000519 · Cited by 48
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J. (2019) · Diabetic Medicine · doi:10.1111/dme.13898 · Cited by 48
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H. Y., & Suissa, S. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14056 · Cited by 48
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs
Corona, G., Isidori, A. M., Aversa, A., Bonomi, M., Ferlin, A., Foresta, C., Vignera, S. L., Maggi, M., Pivonello, R., Vignozzi, L., et al. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09535-7 · Cited by 48
Cai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47
Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0279-z · Cited by 47
Thein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L., Schou, M., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01078-5 · Cited by 48
Is there a role for glucagon‐like peptide‐1 receptor agonists in the treatment of male infertility?
Cannarella, R., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2021) · Andrology · doi:10.1111/andr.13015 · Cited by 47
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139709 · Cited by 47
Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., & Cooper, J. G. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12609 · Cited by 47
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
Hermansen, K., Bohl, M., & Schioldan, A. G. (2015) · Drugs · doi:10.1007/s40265-015-0500-0 · Cited by 47
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 49
JENDLE, J. H., Testa, M. A., Martin, S., Jiang, H. H., & Miličević, Z. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12705 · Cited by 47
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 47
Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes
Madenidou, A., Paschos, P., Karagiannis, T., Katsoula, A., Athanasiadou, E. A., Kitsios, K., Bekiari, E., Matthews, D. R., & Τσάπας, Α. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0443 · Cited by 47
Self-citationFoot self-care in diabetes mellitus: Evaluation of patient awareness
Karadağ, F. Y., Saltoğlu, N., Ak, Ö., Aydın, G., Şenbayrak, S., Erol, S., Özatağ, D. M., Kadanalı, A., Küçükardalı, Y., Çomoğlu, Ş., et al. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.06.003 · Cited by 47
Gebremariam, A. D., Tiruneh, S. A., Ayele, A. A., Tegegn, H. G., Ayele, B. A., & Engidaw, M. T. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100056 · Cited by 47
White, U. A., Fitch, M. D., Beyl, R. A., Hellerstein, M. K., & Ravussin, É. (2020) · Diabetologia · doi:10.1007/s00125-020-05281-7 · Cited by 47
SGLT2 Inhibitors: The Latest “New Kids on the Block”!
Cefalu, W. T., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc14-3048 · Cited by 47
Semaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 47
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Davies, M. J., Russell-Jones, D. L., Selam, J. L., Bailey, T. S., Kerényi, Z., Luo, J., Bue‐Valleskey, J. M., Iványi, T., Hartman, M. L., Jacobson, J. G., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12712 · Cited by 46
Mearns, E. S., Saulsberry, W. J., White, C. M., Kohn, C. G., Lemieux, S., Sihabout, A., Salamucha, I., & Coleman, C. I. (2015) · Diabetic Medicine · doi:10.1111/dme.12837 · Cited by 46
How much is too much? Outcomes in patients using high‐dose insulin glargine
Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L. B., Vlajnic, A., & Rhinehart, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12747 · Cited by 46
Lyu, X., Zhu, X., Zhao, B., Du, L., Chen, D., Wang, C., Liu, G., & Ran, X. (2017) · Scientific Reports · doi:10.1038/srep44865 · Cited by 46
Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
Charbonnel, B. H., Simon, D., Dallongeville, J., Bureau, I., Dejager, S., Lévy-Bachelot, L., Gourmelen, J., & Detournay, B. (2017) · PharmacoEconomics - Open · doi:10.1007/s41669-017-0050-3 · Cited by 46
Khunti, K., Godec, T. R., Medina, J., García-Álvarez, L., Hiller, J., Gomes, M. B., Cid‐Ruzafa, J., Charbonnel, B. H., Fenici, P., Hammar, N., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13083 · Cited by 46
Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
Lévy, A., & Doyen, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.001 · Cited by 46
Karpati, T., Leventer‐Roberts, M., Feldman, B., Cohen-Stavi, C. J., Raz, I., & Balicer, R. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207096 · Cited by 46
Frías, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartášková, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Miličević, Z. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 46
Eurotium Cristatum Fermented Okara as a Potential Food Ingredient to Combat Diabetes
Chan, L. Y., Takahashi, M., Lim, P. J., Aoyama, S., Makino, S., Ferdinandus, F., Ng, S. Y. C., Arai, S., Fujita, H., Tan, H. C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54021-4 · Cited by 46
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 46
Chen, M., Zhang, C., Zhou, N., Wang, X., Su, D., & Qi, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16797 · Cited by 46
Raccah, D., Chou, E., Colagiuri, S., Gaál, Z., Lavalle-Gonzalez, F. J., Mkrtumyan, A. M., Nikonova, E., Tentolouris, N., Vidal, J., & Davies, M. J. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2858 · Cited by 46
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13564 · Cited by 45
Gurney, K., MacConell, L., Malloy, J. L., Zhou, M., & Kolterman, O. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s77290 · Cited by 48
Potent Human α-Amylase Inhibition by the β-Defensin-like Protein Helianthamide
Tysoe, C., Williams, L. K., Keyzers, R. A., Nguyen, N. T., Tarling, C. A., Wicki, J., Goddard‐Borger, E. D., Aguda, A. H., Perry, S., Foster, L. J., et al. (2016) · ACS Central Science · doi:10.1021/acscentsci.5b00399 · Cited by 45
Mamza, J., Mehta, R. L., Donnelly, R., & IDRIS, I. R. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1157263 · Cited by 45
Henry, R. R., KLEIN, E. J., Han, J., & Iqbal, N. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0107 · Cited by 45
Haahr, H. L., Fita, E. G., & Heise, T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0455-7 · Cited by 45
Hydrothermal Duodenal Mucosal Resurfacing
Cherrington, A. D., Rajagopalan, H., MAGGS, D. G., & Deviere, J. M. E. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.002 · Cited by 45
Rodbard, H. W., Tripathy, D., Vidrio-Velázquez, M., Demissie, M., Tamer, S. C., & Piletič, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12955 · Cited by 45
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 45
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D. R., & Vražić, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions
Perreault, L., Vincent, L., Neumiller, J. J., & Cavaiola, T. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.03.180162 · Cited by 45
Iqbal, M. Z., Khan, A. H., Iqbal, M., & Sulaiman, S. A. S. (2019) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_138_19 · Cited by 45
Samya, V., Shriraam, V., Jasmine, A., Venguidesvarane, A. G., Rani, M. A., Durai, V., Gayathri, T., & Mahadevan, S. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719880638 · Cited by 45
Feline comorbidities: Pathophysiology and management of the obese diabetic cat
Clark, M., & Hoenig, M. E. (2021) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x211021540 · Cited by 45
Li, B., Wang, Y., Ye, Z., Yang, H., Cui, X., Wang, Z., & Liu, L. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29831 · Cited by 45
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- American Cancer Society (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-13
- Volume
- 38
- Issue
- 1
- Pages
- 140-149
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2160088494
- Cited by
- 3,066
- References
- 68
- Citations by year
- 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
- FWCI
- 380.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Massachusetts General Hospital
- Yale University
- Kaiser Permanente
- F. Hoffmann-La Roche
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- Intarcia Therapeutics
- National Institute for Health and Care Research
- University of Sydney
- Universiteit van Amsterdam
- University of Toronto
- Novo Nordisk
- Uniwersytet Łódzki
- European Association for the Study of Diabetes
- Université de Nantes
- Servier
- Lilly Deutschland
- University of Ioannina
- School of Medicine, University of Kansas
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
